Canavan disease (CD) is a rare childhood leukodystrophy caused by autosomal recessive mutations in the aspartoacylase (ASPA) gene. Deficiency of ASPA in Canavan patients leads to the accumulation of N- Acetyl-Aspartic Acid (NAA), resulting in swelling and spongy degeneration of white matter in the brain. The clinical manifestations of this fatal disease include psychomotor retardation, muscular hypotonia, macrocephaly, head lag, seizures, and early death. Synthesis of NAA is carried out in the mitochondria of neurons by N-acetyltransferase-8-like (NAT8L) and hydrolyzed in oligodendrocytes by ASPA. Gene replacement therapy for ASPA deficiency is currently the most promising strategy for treating CD. Notably, we have recently achieved full therapeutic correction of the Canavan phenotype in the Aspa knockout (CD-KO) mouse model. A single intravenous injection of recombinant adeno-associated virus packaged with the human ASPA transgene (rAAV-hASPA) at early ages completely resolves neuropathology, resulting in treated animals that outperform wild-types in motor function tests. However, based on strong preliminary evidence, we now hypothesize that the CD phenotype presents a secondary etiology related to metabolism dysfunction. In addition, we recently revealed that overexpression of ASPA in wild type cells in vitro resulted in abnormal mitochondrial shape and function. These findings necessitate further preclinical investigations that focus on: 1) characterizing the possible toxicity of ASPA overexpression in cell types of the CNS and peripheral organs, 2) developing ASPA regulatory cassette(s) that can mimic endogenous physiological levels of ASPA to circumvent adverse effects that may exist due to treatment, and 3) determining the physiological and behavioral effects of ASPA overexpression using a clinically relevant non-human primate model. Our new research strategy now builds on our current promising progress and advances our goals for a safe and effective gene therapy for CD.

Public Health Relevance

Canavan disease (CD) is a rare, childhood-lethal neurodegenerative disorder caused by autosomal recessive mutations in the aspartoacylase gene (ASPA). Recombinant adeno-associated virus (rAAV)-based ASPA gene replacement therapy is currently the most promising strategy for the treatment of CD. We have shown in preclinical studies that treating CD mouse models at neonatal stages with gene therapy can fully cure neurological defects, restore psychomotor function, and extend life. Although, treatments of animals can normalize inborn metabolic error and mitigate neuropathologies, preliminary in vitro analysis suggests that ASPA overexpression may cause dysregulation of cellular energy homeostasis. Here, we propose to investigate whether long-term expression of ASPA delivered by rAAV in both mouse and non-human primate models can lead to unexpected adverse outcomes. In addition, we aim to reduce potential toxicity by reengineering the vector regulatory cassette so that it carries native elements of the ASPA promoter in order to mimic normal ASPA expression. Knowledge gained from our new aims will extend the clinical applicability of rAAV-hASPA to safely and effectively treat CD in patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS076991-07
Application #
9912190
Study Section
Therapeutic Approaches to Genetic Diseases Study Section (TAG)
Program Officer
Morris, Jill A
Project Start
2012-09-01
Project End
2024-01-31
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
Wang, Dan; Li, Jia; Song, Chun-Qing et al. (2018) Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol 36:839-842
Yoon, Yeonsoo; Wang, Dan; Tai, Phillip W L et al. (2018) Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses. Nat Commun 9:412
Wang, Dan; Zhong, Li; Li, Mengxin et al. (2018) Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer. Mol Ther Methods Clin Dev 11:65-72
Zhang, Wei; Li, Linjing; Su, Qin et al. (2018) Gene Therapy Using a miniCEP290 Fragment Delays Photoreceptor Degeneration in a Mouse Model of Leber Congenital Amaurosis. Hum Gene Ther 29:42-50
Tai, Phillip W L; Xie, Jun; Fong, Kaiyuen et al. (2018) Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector Chimeras. Mol Ther Methods Clin Dev 9:130-141
Mendez, Flor M; Núñez, Felipe J; Zorrilla-Veloz, Rocío I et al. (2018) Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres. J Vis Exp :
Wang, Dan; Gao, Guangping (2018) Taking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB. Mol Ther 26:336-338
Wang, Dan; Li, Jia; Tran, Karen et al. (2018) Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space. Hum Gene Ther Methods 29:75-85
He, Xing; Xie, Jun; Wang, Yange et al. (2018) Down-regulation of microRNA-203-3p initiates type 2 pathology during schistosome infection via elevation of interleukin-33. PLoS Pathog 14:e1006957
Kamran, Neha; Alghamri, Mahmoud S; Nunez, Felipe J et al. (2018) Current state and future prospects of immunotherapy for glioma. Immunotherapy 10:317-339

Showing the most recent 10 out of 55 publications